159 related articles for article (PubMed ID: 31353059)
1. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract][Full Text] [Related]
2. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
3. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.
Follini E; Marchesini M; Roti G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226848
[TBL] [Abstract][Full Text] [Related]
5. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
6. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
7. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
8. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.
Samuels AL; Heng JY; Beesley AH; Kees UR
Br J Haematol; 2014 Apr; 165(1):57-66. PubMed ID: 24456076
[TBL] [Abstract][Full Text] [Related]
9. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
10. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
Silveira AB; Laranjeira AB; Rodrigues GO; Leal PC; Cardoso BA; Barata JT; Yunes RA; Zanchin NI; Brandalise SR; Yunes JA
Oncotarget; 2015 May; 6(15):13105-18. PubMed ID: 25869207
[TBL] [Abstract][Full Text] [Related]
11. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Kośmider K; Karska K; Kozakiewicz A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409154
[TBL] [Abstract][Full Text] [Related]
14. A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Banerjee K; Das S; Sarkar A; Chatterjee M; Biswas J; Choudhuri SK
Biomed Pharmacother; 2016 Dec; 84():71-92. PubMed ID: 27639544
[TBL] [Abstract][Full Text] [Related]
15. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
16. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
17. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
18. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
19. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
20. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of
Kuzilková D; Bugarin C; Rejlova K; Schulz AR; Mei HE; Paganin M; Biffi A; Biondi A; Kalina T; Gaipa G
Haematologica; 2022 Jun; 107(6):1293-1310. PubMed ID: 34670357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
